Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...
California biotech Replicate Biosciences will receive up to $550 million from Novo Nordisk in an alliance that aims to track down new drugs for obesity and diabetes. The partners will develop new ...
Novo Nordisk is again looking for help outside its own laboratories as it works to build on the success of Ozempic and its sister medicine Wegovy. In the latest deal, Novo will provide research ...
Replicate Bioscience and Novo Nordisk collaborate to develop srRNA-based therapies for obesity, type 2 diabetes, and cardiometabolic diseases. Novo Nordisk receives an exclusive worldwide license to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results